Julie Trolle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julie Trolle has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Jef D. Boeke
Institute for Systems Genetics, Department of Biochemistry and Molecular Pharmacology, NYU Langone Health, New York, USA
3 shared publications Sofia Sessa
Institute for Systems Genetics, Department of Biochemistry and Molecular Pharmacology, NYU Langone Health, New York, USA
2 shared publications- Sudarshan Pinglay
Department of Genome Sciences, University of Washington, Seattle, WA, USA
2 shared publications - Tori Rodrick
Department of Biochemistry and Molecular Pharmacology, NYU Langone Health, New York, USA
2 shared publications Aleksandra Wudzinska
Institute for Systems Genetics, Department of Biochemistry and Molecular Pharmacology, NYU Langone Health, New York, USA
1 shared publicationAndrew Kaufman
Department of Systems Biology, Columbia University
1 shared publication
Latest Publications
- Open Access
- 6 October 2026
- Published by Springer Nature in Nature Biotechnology
- p. 1-15
Highly multiplexed mammalian metabolic engineering with a shotgun approach
- 6 October 2026
- Published by Springer Nature in Nature Biotechnology
- p. 1-15
Open AccessHighly multiplexed mammalian metabolic engineering with a shotgun approach
- Open Access
A shotgun approach for highly multiplexed mammalian metabolic engineering
Mammalian metabolic engineering is critical to advancing basic biology, bioproduction, and cell therapy. However, as pathway complexity increases, so does the size of both the combinatorial design space and the DNA constructs required, rendering unbiased screens intractable. To address this, we developed Shotgun Genetic Engineering (SGE), a scalable approach that exploits the ease of delivering many barcoded small constructs—rather than a single large one—into mammalian cells. This allows each cell to serve as an independent experiment, carrying a unique synthetic metabolic pathway that explores combinations of gene content, stoichiometry, and organellar localization. Functional pathways are identified by sequencing barcodes from cells exhibiting the desired phenotype. Using SGE, we screened millions of pathway combinations to engineer essential amino acid biosynthesis in two mammalian cell lines (CHO and Jurkat), achieving near-wild-type growth in valine-free medium and, for the first time, enabling isoleucine prototrophy in CHO cells. Successful solutions favored mitochondrial localization and required integration of 23–52 kb of synthetic DNA—lengths that are impractical to screen by conventional methods. The resulting datasets are compatible with machine learning frameworks, positioning SGE as a powerful platform for decoding and engineering complex biosynthetic traits in mammalian systems.
Open AccessA shotgun approach for highly multiplexed mammalian metabolic engineering
Mammalian metabolic engineering is critical to advancing basic biology, bioproduction, and cell therapy. However, as pathway complexity increases, so does the size of both the combinatorial design space and the DNA constructs required, rendering unbiased screens intractable. To address this, we developed Shotgun Genetic Engineering (SGE), a scalable approach that exploits the ease of delivering many barcoded small constructs—rather than a single large one—into mammalian cells. This allows each cell to serve as an independent experiment, carrying a unique synthetic metabolic pathway that explores combinations of gene content, stoichiometry, and organellar localization. Functional pathways are identified by sequencing barcodes from cells exhibiting the desired phenotype. Using SGE, we screened millions of pathway combinations to engineer essential amino acid biosynthesis in two mammalian cell lines (CHO and Jurkat), achieving near-wild-type growth in valine-free medium and, for the first time, enabling isoleucine prototrophy in CHO cells. Successful solutions favored mitochondrial localization and required integration of 23–52 kb of synthetic DNA—lengths that are impractical to screen by conventional methods. The resulting datasets are compatible with machine learning frameworks, positioning SGE as a powerful platform for decoding and engineering complex biosynthetic traits in mammalian systems.
- Open Access
- 27 September 2022
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
Resurrecting essential amino acid biosynthesis in mammalian cells
Major genomic deletions in independent eukaryotic lineages have led to repeated ancestral loss of biosynthesis pathways for nine of the twenty canonical amino acids. While the evolutionary forces driving these polyphyletic deletion events are not well understood, the consequence is that extant metazoans are unable to produce nine essential amino acids (EAAs). Previous studies have highlighted that EAA biosynthesis tends to be more energetically costly, raising the possibility that these pathways were lost from organisms with access to abundant EAAs. It is unclear whether present-day metazoans can reaccept these pathways to resurrect biosynthetic capabilities that were lost long ago or whether evolution has rendered EAA pathways incompatible with metazoan metabolism. Here, we report progress on a large-scale synthetic genomics effort to reestablish EAA biosynthetic functionality in mammalian cells. We designed codon-optimized biosynthesis pathways based on genes mined from Escherichia coli. These pathways were de novo synthesized in 3 kilobase chunks, assembled in yeasto and genomically integrated into a Chinese hamster ovary (CHO) cell line. One synthetic pathway produced valine at a sufficient level for cell viability and proliferation. 13C-tracing verified de novo biosynthesis of valine and further revealed build-up of pathway intermediate 2,3-dihydroxy-3-isovalerate. Increasing the dosage of downstream ilvD boosted pathway performance and allowed for long-term propagation of second-generation cells in valine-free medium at 3.2 days per doubling. This work demonstrates that mammalian metabolism is amenable to restoration of ancient core pathways, paving a path for genome-scale efforts to synthetically restore metabolic functions to the metazoan lineage.
- 27 September 2022
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
Open AccessResurrecting essential amino acid biosynthesis in mammalian cells
Major genomic deletions in independent eukaryotic lineages have led to repeated ancestral loss of biosynthesis pathways for nine of the twenty canonical amino acids. While the evolutionary forces driving these polyphyletic deletion events are not well understood, the consequence is that extant metazoans are unable to produce nine essential amino acids (EAAs). Previous studies have highlighted that EAA biosynthesis tends to be more energetically costly, raising the possibility that these pathways were lost from organisms with access to abundant EAAs. It is unclear whether present-day metazoans can reaccept these pathways to resurrect biosynthetic capabilities that were lost long ago or whether evolution has rendered EAA pathways incompatible with metazoan metabolism. Here, we report progress on a large-scale synthetic genomics effort to reestablish EAA biosynthetic functionality in mammalian cells. We designed codon-optimized biosynthesis pathways based on genes mined from Escherichia coli. These pathways were de novo synthesized in 3 kilobase chunks, assembled in yeasto and genomically integrated into a Chinese hamster ovary (CHO) cell line. One synthetic pathway produced valine at a sufficient level for cell viability and proliferation. 13C-tracing verified de novo biosynthesis of valine and further revealed build-up of pathway intermediate 2,3-dihydroxy-3-isovalerate. Increasing the dosage of downstream ilvD boosted pathway performance and allowed for long-term propagation of second-generation cells in valine-free medium at 3.2 days per doubling. This work demonstrates that mammalian metabolism is amenable to restoration of ancient core pathways, paving a path for genome-scale efforts to synthetically restore metabolic functions to the metazoan lineage.